Pacific Edge Provides Update on Kaiser EMR Integration

31 March 2023
PACIFIC EDGE PROVIDES UPDATE ON KAISER EMR INTEGRATION

DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today
announces it has completed the software development and integration testing on its project to
integrate Cxbladder into the Electronic Medical Records (EMR) system of Kaiser Permanente.
We are now completing the administrative and review processes to enable the project to go live.
Pacific Edge will continue to provide regular updates on our progress on a quarterly basis in our
shareholder updates until the project is completed, and any material announcements in accordance
with our NZX continuous disclosure obligations.
Pacific Edge Chief Executive Dr Peter Meintjes said: “We are excited to have achieved the important
technical milestones in the project, which has spanned many teams and many person-hours across
the Kaiser system, our team in the US, and our team in New Zealand.
“We have significantly de-risked the project and importantly, the Kaiser urologists, innovation
group, EMR implementation team and Pacific Edge team continue to share a common goal and a
common commitment to completion as soon as feasible.”
According to Dr Ronald Loo, MD, a urologist with Kaiser Permanente Southern California
Permanente Medical Group, the Cxbladder tests have improved access to urology care as Kaiser has
emerged from the pandemic with unprecedented demand for services.
“The very high negative predictive value of the Cxbladder tests have allowed us to improve access
by safely reducing overwhelming demand for screening and surveillance cystoscopy. It’s proven to
be a quadruple win: convenient and preferred by our members, high quality - reliable results, cost
effective for the organization, and a sustainable way to improve the wellbeing of our healthcare
teams," Dr Loo said.
Kaiser Permanente is the largest integrated healthcare provider in the US, serving 12.6 million
members, which equates to approximately 3.7% of the population in the USA. It operates 39
hospitals, more than 700 medical offices, and employs 23,656 physicians and 65,000 nurses.

Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.
For more information:
Dr Peter Meintjes Richard Inder
Chief Executive The Project
Pacific Edge P: 021 645 643
P: 022 032 1263

OVERVIEW www.pacificedgedx.com
Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and
commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or
surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder
tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

About Cxbladder www.cxbladder.com
Cxbladder is a non-invasive genomic urine test optimized for the detection and management of bladder cancer. The
Cxbladder evidence portfolio developed over the past 14 years includes more than 20 peer reviewed publications for
primary detection, surveillance, adjudication of atypical urine cytology and equivocal cystoscopy. Cxbladder is the focal
point of numerous ongoing and planned clinical studies to generate an ever-increasing body of clinical utility evidence
supporting adoption and use in the clinic to improve patient health outcomes. Cxbladder is reimbursed by CMS and has
been trusted by over 2,000 US urologists in the diagnosis and management of more than 80,000 patients, including the
option for in-home sample collection. In New Zealand, Cxbladder is accessible to 75% of the population via public
healthcare and all residents have the option of buying the test online.